REC-2282
REC-2282-201
Phase 3 small_molecule terminated
Quick answer
REC-2282 for Neurofibromatosis Type 2 is a Phase 3 program (small_molecule) at RECURSION PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- RECURSION PHARMACEUTICALS, INC.
- Indication
- Neurofibromatosis Type 2
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated